1. Home
  2. AGEN vs ATLQ Comparison

AGEN vs ATLQ Comparison

Compare AGEN & ATLQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agenus Inc.

AGEN

Agenus Inc.

N/A

Current Price

$7.71

Market Cap

274.8M

Sector

Health Care

ML Signal

N/A

ATLQ

JAB Acquisition Corp I Class A Ordinary Shares

N/A

Current Price

$9.98

Market Cap

283.6M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
AGEN
ATLQ
Founded
1994
2026
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
274.8M
283.6M
IPO Year
1999
2026

Fundamental Metrics

Financial Performance
Metric
AGEN
ATLQ
Price
$7.71
$9.98
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $26.33
N/A
AVG Volume (30 Days)
★ 1.1M
19.8K
Earning Date
11-09-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 100.00
N/A
EPS
★ 0.96
N/A
Revenue
★ $42,877,086.00
N/A
Revenue This Year
$9.64
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$7.85
★ N/A
Revenue Growth
★ 89.95
N/A
52 Week Low
$2.71
$9.96
52 Week High
$10.19
$9.99

Technical Indicators

Market Signals
Indicator
AGEN
ATLQ
Relative Strength Index (RSI) 46.32 53.76
Support Level $6.51 N/A
Resistance Level $8.64 $9.99
Average True Range (ATR) 0.63 0.01
MACD -0.18 0.00
Stochastic Oscillator 14.75 78.80

Price Performance

Historical Comparison
AGEN
ATLQ

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

About ATLQ JAB Acquisition Corp I Class A Ordinary Shares

JAB Acquisition Corp I is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.

Share on Social Networks: